Physician profile
Jonathan A Beatty
NPI 1205028149
$46,122.16
in general payments reported to CMS, 2019-2025
15 companies · $39.58 in 2025
The $39.58 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $20K · 2021: $1,150 · 2022: $23.60 · 2023: $152 · 2024: $604 · 2025: $39.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.53 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $45,183.95 | 2019-2025 | Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $177.90 | 2019-2024 | Spravato |
| Boston Scientific Corporation | $165.18 | 2024 | |
| Indivior INC. | $136.17 | 2019-2024 | Sublocade |
| Axsome Therapeutics, INC. | $125.86 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $68.86 | 2023-2024 | Austedo Xr |
| Bausch Health US, LLC | $44.66 | 2024 | Aplenzin |
| Neuronetics, INC. | $39.16 | 2019 | |
| Braeburn INC. | $35.24 | 2023-2024 | Brixadi |
| Neurocrine Biosciences, INC. | $33.83 | 2024 | Ingrezza |
| Spr Therapeutics, INC | $31.62 | 2024 | Sprint Pns System |
| Ibsa Pharma INC. | $24.73 | 2025 | Flector, Tirosint, Licart |
| Nalu Medical, INC. | $24.67 | 2024 | Nalu Neurostimulation System |
| Sunovion Pharmaceuticals INC. | $18.04 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Beatty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.